BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220925T090000
DTEND;TZID=Europe/Brussels:20220928T180000
DTSTAMP:20260526T205745
CREATED:20220518T092049Z
LAST-MODIFIED:20220518T092902Z
UID:4721-1664096400-1664388000@www.europabio.org
SUMMARY:14th Carbohydrate Bioengineering Meeting (CBM14)
DESCRIPTION:Carbohydrate Bioengineering is recognized today as a pillar of biotechnology and biological engineering. It offers major assets to face many of our modern life challenges\, promote innovative medical treatments or elaborate functional food\, biopharmaceuticals\, active cosmetics\, biomaterials\, to name just a few. In particular\, researches in glycobiology\, multi-omic data integration\, structure/function relationships\, enzyme engineering\, biocatalysis\, biophysics and process development are key drivers to expand opportunities in this field. More than ever\, knowledge between carbohydrate players must be shared and crossing and bridging the disciplinary boundaries are essential to open new horizons of developments for the benefit of all. This will be the objective of CBM14. \n\n\n\nIn keeping with the previous CBMs\, the conference will bring together glycoscientists coming from all over the world to share their latest findings and most exciting achievements in a friendly and warm atmosphere. Experts from research institutions or private companies will open each session\, which will be followed by presentations selected from submitted abstracts. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-international-congress-on-biocatalysis-biocat2022/
LOCATION:Oslo/Norefjell\, Norway\, Norway
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-8.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220828T090000
DTEND;TZID=Europe/Brussels:20220901T180000
DTSTAMP:20260526T205745
CREATED:20220524T101421Z
LAST-MODIFIED:20220524T101423Z
UID:4761-1661677200-1662055200@www.europabio.org
SUMMARY:10th International Congress on Biocatalysis (biocat2022)
DESCRIPTION:The transition from fossil to a biobased circular economy requires cutting edge technologies that ensure economic growth with environmentally responsible action.   \n\n\n\nThe future challenges which include utilization of natural resources\, food supply\, health\, energy and the environment\, can only be met in an interdisciplinary manner. \n\n\n\nBiocatalysis is one of the key technologies to address this complex task. Biotechnological products already find application in food\, feed\, chemical\, pharmaceutical and cosmetics industry and the developing sustainable bioeconomy is expected to create new processes and products and new job opportunities.   \n\n\n\nThe successful concept of biocat congress is aimed at integrating the know-how of highly acknowledged biologists\, biochemists\, chemists and engineers from academia and industry. Biocat congress offers a platform to form strategic alliances for future projects and innovations.   \n\n\n\nSince 2002 we have been organizing the biennial biocat conference series\, which is focused on the rapidly evolving fields of biocatalysis and industrial biotechnology. The preceding International Congresses on Biocatalysis attracted more than 3\,200 participants from over 40 countries. \n\n\n\n The major topics to be addressed are:  \n\n\n\nComputational analysis for enzyme discovery and designStructure-function analysis and enzyme optimizationEnzymatic and whole-cell biotransformationReaction cascades: Bioelectrochemical as well as chemo-/photoenzymaticBioprocess engineeringSynthesis of biodegradable materials and energy generationCarbon dioxide based biotechnologySustainable industrial processes\, biorefinery and bioeconomy\n\n\n\nIt is our aim to create a stimulating and open scientific atmosphere to foster the development of new collaborations.   \n\n\n\nIt is our great pleasure and honor to invite scientists from all over the world to the 10th International Congress on Biocatalysis 2022 (biocat2022) to be held from 28 August – 1 September 2022 at the Hamburg University of Technology (TUHH)\, Hamburg\, Germany. \n\n\n\nWe are looking forward to welcoming you in Hamburg\, an exciting and cosmopolitan city\, and to share a successful and enjoyable meeting in person with you. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-international-congress-on-biocatalysis-biocat2022-2/
LOCATION:Hamburg University of Technology (TUHH)\, Am Schwarzenberg-Campus 1\, Hamburg\, 21073\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220826T140000
DTEND;TZID=Europe/Brussels:20220826T160000
DTSTAMP:20260526T205745
CREATED:20220819T074007Z
LAST-MODIFIED:20220819T074008Z
UID:5045-1661522400-1661529600@www.europabio.org
SUMMARY:ESAB Webinar: Synthetic Biology and Metabolic Engineering Tools and Methodologies
DESCRIPTION:14:00-14:30Phage-assisted directed evolution of proteinsProf. Dr. Alfonso JaramilloInstituto de Biologia Integrativa de Sistemas (i2SysBio)\, CSIC\, Valencia\, Spain14:30-15:00 Engineered bacteria as an early-stage drug discovery platform for protein misfolding diseasesProf. Dr. Georgios SkretasDirector\, Institute for Bio-innovation\, Biomedical Sciences Research Center “Alexander Fleming”\, Athens\, Greece15:00-15:30Biochemical engineering drives the green transitionProf. Dr. Sotirios C. KampranisBiochemical Engineering Group\, Department of Plant and Environmental Sciences\, University of Copenhagen\, Frederiksberg C\, Denmark15:30-16:00 Cell-free synthetic biology enables industrial biotechnologyProf. Dr. Ashty KarimDepartment of Chemical and Biological Engineering and Director of Research for the Center for Synthetic Biology at Northwestern University\, Evanston\, IL 60208\, USA\n\n\n\n \n\n\n\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/esab-webinar-synthetic-biology-and-metabolic-engineering-tools-and-methodologies/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/08/2022-08-19-09_38_58-ESAB_Webinar_26AUGUST2022Flyer.pdf-Adobe-Acrobat-Pro-DC-64-bit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220729T090000
DTEND;TZID=Europe/Brussels:20220729T190000
DTSTAMP:20260526T205745
CREATED:20220726T091451Z
LAST-MODIFIED:20220726T091453Z
UID:5008-1659085200-1659121200@www.europabio.org
SUMMARY:Biocatalysis and Molecular Medcine
DESCRIPTION:ESAB and SKB are pleased to invite you to the Webinar on the new topic Biocatalysis and Molecular Medicine\, bridging the communities of biocatalysis/industrial biotechnology and molecular medicine. \n\n\n\n10:00 – 10:30 CESTCritical mechanisms in the pathogenesis of persistent bacterial infections Prof. Dr. Thomas F. MeyerMax Planck Institute for Infection Biology\, Department of Molecular Biology\, Berlin\, and Laboratory of Infection Oncology\, Institute of Clinical Molecular Biology\, Christian Albrecht’s University of Kiel and University Hospital Schleswig Holstein – Campus Kiel\, Germany10:30 – 11:00 CESTMucopolysaccharidoses – molecular mechanisms and treatment options of disorders caused by defects in biocatalysis of glycosaminoglycan decay  Prof. Dr. Grzegorz WegrzynDepartment of Molecular Biology\, Faculty of Biology\, University of Gdansk\, Wita Stwosza 59\, 80-308 Gdansk\, Poland11:00 – 11:30 CESTBiocatalysis in Cells through Proteolysis Targeting Chimeras (PROTACs): How to Improve Cell Permeability and Achieve Successful Protein Degradation Prof. Dr. Leonardo ScapozzaSchool of Pharmaceutical Sciences\, and Institute of Pharmaceutical Sciences of Western Switzerland\, University of Geneva\, Switzerland11:30 – 12:00 CESTThe use of systems biology in treatment of liver diseases Prof. Dr. Adil MardinogluScience for Life Laboratory\, KTH – Royal Institute of Technology\, Stockholm\, Sweden\, and Centre for Host-Microbiome Interactions\, Faculty of Dentistry\, Oral & Craniofacial Sciences\, King’s College London\, London\, United Kingdom\n\n\n\nESAB-SKB_Webinar_29JULY2022Download
URL:https://www.europabio.org/event/biocatalysis-and-molecular-medcine/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/07/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220705T090000
DTEND;TZID=Europe/Brussels:20220708T180000
DTSTAMP:20260526T205745
CREATED:20220518T091432Z
LAST-MODIFIED:20220518T091433Z
UID:4714-1657011600-1657303200@www.europabio.org
SUMMARY:10th OxiZymes meeting
DESCRIPTION:Welcome to the 10th Edition of OxiZymes meeting!   \n\n\n\nInitially specifically devoted to research activities on laccases and peroxidases\, this series of conferences now cover the whole class of oxidoreductases. Building on the success of previous OxiZymes meetings\, OxiZymes 2022 will emphasize the discovery of new oxidoreductases and the latest advances in their biotechnological applications. The conference will provide a unique opportunity for industrial researchers to meet with foremost young academics for knowledge transfer and to establish research collaborations. The conference format is designed to be highly interactive\, with ample time for stimulating discussions\, interdisciplinary interactions\, and meetings alongside the scientific sessions. \n\n\n\nOxiZymes Siena will cover the following topics: \n\n\n\nNewly discovered OxizymesOxizymes mechanism and structureOxizymes engineering\, computational and biomimetic approachesOxizymes in fine chemistryBiotechnological applications of Oxizymes:Oxizymes in foodOxizymes in biorefineryOxizymes in biosensorsOxizymes in biomaterials applicationsSophie Vanhulle Prize 2022\n\n\n\nThe best poster and presentation will be awarded by MDPI with 200 CHF each. \n\n\n\nThe Organizing Committee is looking forward to welcoming you in Siena! \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-oxizymes-meeting/
LOCATION:University of Siena\, Via Roma 56\, Siena\, 53100\, Italy
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220624T020000
DTEND;TZID=Europe/Brussels:20220624T160000
DTSTAMP:20260526T205745
CREATED:20220524T095433Z
LAST-MODIFIED:20220623T152259Z
UID:4758-1656036000-1656086400@www.europabio.org
SUMMARY:Biocatalytic and Sustainable Chemistry: Biocatalysis and Renewables
DESCRIPTION:The next webinar of the European Society of Applied Biocatalysis (ESAB)\, this time together with SusChem\, will take place on Friday\, 24 June 2022 (14:00-16:00 CEST). \n\n\n\nThe topic is “Biocatalytic and Sustainable Chemistry: Biocatalysis and Renewables”. \n\n\n\nYou can look forward to the following lectures: \n\n\n\n14:00 – 14:30 CESTBiocatalysis – Opportunities and challenges for industrial production Prof. Dr. Stefan Buchholz\, Head of R&D for the Division Nutrition & Care\, Evonik Operations GmbH\, Germany14:30 – 15:00 CESTBiotransformations as Key Steps in the Conversion of Unsaturated Fatty Acids into Industrial Chemicals Prof. Dr. Harald Gröger\, Department of Chemistry\, Industrial Organic Chemistry and Biotechnology\, Bielefeld University\, Germany15:00 – 15:30 CESTChemobiocatalytic upgrading of furfural to C4 chemicals Prof. Dr. Ning Li\, School of Food Science and Technology\, South China University of Technology\, Guangzhou 510640\, China15:30 – 16:00 CESTEnzymes for converting chitin/chitosans into highly valuable products Prof. Dr. Bruno Moerschbacher\, Institute of Plant Physiology and Ecology\, Münster University\, Germany\n\n\n\n \n\n\n\n \n\n\n\nPlease be informed\, that\, immediately after the registration\, you will receive an email confirmation with the Zoom link. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/9th-biorizon-annual-event-on-bio-aromatics/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/06/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220615T200000
DTEND;TZID=Europe/Brussels:20220615T210000
DTSTAMP:20260526T205745
CREATED:20220505T095121Z
LAST-MODIFIED:20220510T112747Z
UID:4448-1655323200-1655326800@www.europabio.org
SUMMARY:EuropaBio: BIO 2022
DESCRIPTION:BIO 2022: The big bang in pharma legislation: A European epicentre shaping global healthcare and competitive industry \n\n\n\n\n\nEuropaBio is pleased to lead a panel discussion at BIO in San Diego and invites all delegates to join us to discuss the future of healthcare innovation as impacted by European changes. \n\n\n\n20 years ago\, European pharmaceutical legislation underwent a major review\, a critical point in the continent’s single market in healthcare.  Since then Europe has grown\, bringing new voices\, political momentum and advanced technologies into healthcare and today\, the European Commission is reshaping pharma legislation to meet the twin priorities of equality of access and ability to pay. \n\n\n\nThis is a significant moment for the global biopharmaceutical industry and one that will change the dynamics of investment\, science and market access for companies worldwide. \n\n\n\nHow does the legislative framework for medicines achieve its aims through reform? Balancing equity and affordability of medicines with reward for high-risk innovation from SMEs through to multi-nationals. \n\n\n\nPanel focus: \n\n\n\nThe drive for reform – the world is changing and with it must change the pathway for medicines so that all patients benefitWhat do SMEs\, mid-sized and multi-national companies need from legislation to ensure they can deliver innovation in the long term?When change is inevitable\, how does industry roll up its shelves and help collectively drive a new future\, rather than waiting for it to be imposed?How will European reform impact the global biopharma sector in a time of geopolitical realignment and regrowth?\n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/europabio-bio-2022/
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/inline_large_bio2022-linkedin-banner.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220614T083000
DTEND;TZID=Europe/Brussels:20220614T170000
DTSTAMP:20260526T205745
CREATED:20220504T152551Z
LAST-MODIFIED:20220506T112237Z
UID:4423-1655195400-1655226000@www.europabio.org
SUMMARY:IHI Kick-off and brokerage event
DESCRIPTION:The Innovative Health Initiative (IHI) is launching its first calls for proposal in late June and it is time to start thinking about building partnerships at our kick-off and brokerage event. This one-day hybrid event will take place on 14 June 2022 at Hotel Le Plaza Brussels\, where creating project proposals and building strong\, effective consortia are at the core of the day. We aim to provide pertinent information; allow open and honest discussion as well as network building through face-to-face and virtual meetings. \n\n\n\nIn the first session\, IHI will present the content of the calls and outline the rules for participation. Topics covered will be the research priorities of IHI\, call conditions\, and even specific opportunities for SMEs. \n\n\n\nThe second session is the moment for consortia building. In the room\, there will be available timeslots to make short elevator pitches on your proposals. \n\n\n\nWhether you are in the room or in a virtual environment\, you will be able to book meetings through an online platform with representatives who have an interest in the same topics. This is a great opportunity to have face-to-face or virtual project idea discussions and to find partners to build a strong consortium. \n\n\n\nThere will be coffee breaks and lots of time for questions and answers to get you rolling before the dedicated networking sessions. \n\n\n\nParticipation in the event will be free of charge! However\, registration and profile activation will be mandatory to attend the brokerage event. A networking lunch will be provided for those in the room. \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/ihi-kick-off-and-brokerage-event%ef%bf%bc/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220605T090000
DTEND;TZID=Europe/Brussels:20220608T180000
DTSTAMP:20260526T205745
CREATED:20220518T084744Z
LAST-MODIFIED:20220518T085000Z
UID:4705-1654419600-1654711200@www.europabio.org
SUMMARY:6th International Conference Implementation of Microreactor Technology in Biotechnology
DESCRIPTION:We cordially invite you to attend the 6th International Conference IMPLEMENTATION OF MICROREACTOR TECHNOLOGY IN BIOTECHNOLOGY – IMTB 2022\, which will take place in Portorož\, Slovenia\, from 5th to 8th June 2022. \n\n\n\nThe IMTB conference aims to provide a platform for people from industry and academia\, working in the cross-section of microfluidics\, life sciences\, analytics\, and bioprocess engineering. The interdisciplinary feature of the IMTB conferences enables participants to present and discuss their latest results\, developments\, and strategies within these complementary fields and to integrate them to gain new accomplishments for industrial implementation. \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/6th-international-conference-implementation-of-microreactor-technology-in-biotechnology/
LOCATION:Portorož\, Slovenia\, Slovenia
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220602T150000
DTEND;TZID=Europe/Brussels:20220602T161500
DTSTAMP:20260526T205745
CREATED:20220510T072627Z
LAST-MODIFIED:20220517T120255Z
UID:4513-1654182000-1654186500@www.europabio.org
SUMMARY:Rare Conversations 2022!
DESCRIPTION:Managing uncertainties in rare disease innovation\n\n\n\n\n\nJoins us for the new episode of Rare Conversations 2022! \n\n\n\nThe second episode of Rare Conversations 2022 will build on the previous Conversation about game-changing opportunities in rare disease R&D. In the first episode\, different experts convened on the existence of opportunities in rare diseases\, that still face obstacles that need to be addressed. This event is meant to discuss and propose solutions on: “Managing uncertainties in rare disease innovation”
URL:https://www.europabio.org/event/rare-conversations-2022-2/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220601T170000
DTEND;TZID=Europe/Brussels:20220601T183000
DTSTAMP:20260526T205745
CREATED:20220506T084016Z
LAST-MODIFIED:20220506T084403Z
UID:4501-1654102800-1654108200@www.europabio.org
SUMMARY:Roundtable on leveraging private investment in health and life sciences
DESCRIPTION:Investments in health innovation will be central to ensure better preparedness as we are aiming both to recover from the pandemic and to better anticipate future health challenges.We are pleased to invite you to the launch of a novel report on European life science and health investment attractiveness as well as an exclusive conversation with global sector representatives on 1 June at 4:00 pm CET.  \n\n\n\nThree reasons to join: \n\n\n\nExplore the nexus between the private investment and health agendasDiscuss how policy makers can scale up investments in health and life science innovationExchange with industry experts\, OECD and government representatives\n\n\n\nWe look forward to your participation. For more information\, please contact Ina Sandler. \n\n\n\n\n\n\n\n\nRegister now\n\n\n\nBrowse the agenda
URL:https://www.europabio.org/event/roundtable-on-leveraging-private-investment-in-health-and-life-sciences/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220601T090000
DTEND;TZID=Europe/Brussels:20220603T180000
DTSTAMP:20260526T205745
CREATED:20220518T082604Z
LAST-MODIFIED:20220518T084801Z
UID:4699-1654074000-1654279200@www.europabio.org
SUMMARY:18th International Conference on Renewable Resources and Biorefineries (RRB 2022)
DESCRIPTION:Biobased solutions for climate change\n\n\n\n\n\nThe 18th edition of the International Conference on Renewable Resources & Biorefineries will take place in Bruges\, Belgium from Wednesday 1 June until Friday 3 June 2022. Based on the previous RRB conferences\, this conference is expected to welcome about 300 international participants from over 30 countries.Delegates from universities\, industry\, governmental and non-governmental organizations\, and venture capital providers will present their views on industrial biotechnology\, sustainable (green) chemistry\, and agricultural policy related to the use of renewable raw materials for non-food applications and energy supply. The conference further aims at providing an overview of the scientific\, technical\, economic\, environmental and social issues of renewable resources and biorefineries in order to give an impetus to the biobased economy and to present new developments in this area. The conference will provide a forum for leading political\, corporate\, academic\, and financial people to discuss recent developments and set up collaborations.The three-day international conference will consist of plenary lectures\, oral presentations\, poster sessions\, and an exhibition. Companies and research organizations are offered the opportunity to organize a satellite symposium.  \n\n\n\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/18th-international-conference-on-renewable-resources-and-biorefineries-rrb-2022/
LOCATION:BMCC – Bruges Meeting and Convention Centre\, Beursplein 1\, Bruges\, 8000\, Belgium
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220531T110000
DTEND;TZID=Europe/Brussels:20220531T123000
DTSTAMP:20260526T205746
CREATED:20220427T080004Z
LAST-MODIFIED:20220503T075144Z
UID:4371-1653994800-1654000200@www.europabio.org
SUMMARY:SME BioForum
DESCRIPTION:Advanced Therapy Medicinal Products (ATMPs) in Europe \n\n\n\n\n\nOn May 31st\, from 11h to 12h30 CET\, EuropaBio – the European Association for Bioindustries\, will host the first online round table discussion within its new SME BioForum. This online and invite-only meeting will focus on the business environment in Europe for Advanced Therapy Medicinal Products (ATMPs) in Europe. Selected SMEs are being invited by their biotechnology association which sits within EuropaBio. \n\n\n\nThe SME BioForum will bring together senior executives from Europe’s growing SMEs within ATMPs. The moderated discussion will address commercial development challenges and how the European regulatory and market access landscape influences their growth and delivery of products to patients. \n\n\n\nFrom this BioForum\, EuropaBio and its National Association Council will undertake direct advocacy on SME priorities to key stakeholders at the national and European levels to address the legislation\, regulatory\, finance and market access issues that impact SME competitiveness. \n\n\n\nBy participating in this BioForum\, SME executives have their voices heard and represented at the highest levels in Europe. \n\n\n\nParticipants should be at senior management level\, with the ability to debate their company’s challenges for sustainable growth to profit and current developments in their national biotechnology context within their field of expertise. There is no requirement for participants to be knowledgeable of or involved in policy efforts. \n\n\n\nIf you have any queries or wish for further details\, please get in touch with José Peres at j.peres@europabio.org.
URL:https://www.europabio.org/event/sme-bioforum/
CATEGORIES:SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/04/Event-Page.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220527T100000
DTEND;TZID=Europe/Brussels:20220527T120000
DTSTAMP:20260526T205746
CREATED:20220524T074459Z
LAST-MODIFIED:20230118T092711Z
UID:4751-1653645600-1653652800@www.europabio.org
SUMMARY:ESAB Webinar: Biocatalytic Total Synthesis
DESCRIPTION:10:00 – 10:30 CESTWhat the archaeal genomes tell usProf. Dr. Haruyuki AtomiDepartment of Synthetic Chemistry and Biological Chemistry\, Graduate School of Engineering\, Kyoto University\, Kyoto\, and Core Research for Evolutional Science and Technology (CREST)\, Japan Science and Technology Agency (JST)\, Tokyo\, Japan10:30 – 11:00 CESTBiosynthesis of StrychnineDr. Benke HongDepartment of Natural Product Biosynthesis\, Max Planck Institute for Chemical Ecology\, Jena\, Germany11:00 – 11:30 CESTBamboo and Crop Leaves Biosynthesize Antinociceptive C-glycosylated FlavonesProf. Dr. Yong WangKey Laboratory of Synthetic Biology\, CAS\, CAS Center for Excellence in Molecular Plant Science (CEMPS)\, Institute of Plant Physiology and Ecology\, Chinese Academy of Sciences (CAS)\, Shanghai\, China11:30 – 12:00 CESTDiscovery\, characterization and engineering synthetic pathways to bioactive moleculesProf. Dr. Jason MicklefieldDepartment of Chemistry and Manchester Institute of Biotechnology\, The University of Manchester\, Manchester\, UK\n\n\n\n \n\n\n\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/esab-webinar-biocatalytic-total-synthesis/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220518T080000
DTEND;TZID=Europe/Brussels:20220519T170000
DTSTAMP:20260526T205746
CREATED:20220308T173908Z
LAST-MODIFIED:20220505T094810Z
UID:4166-1652860800-1652979600@www.europabio.org
SUMMARY:Knowledge for Growth | Ghent
DESCRIPTION:Knowledge for Growth is Europe’s finest life sciences conference and will take place both on-site (Ghent\, Belgium) and on-line\, in May 2022. \n\n\n\nThe cream of the Belgian life sciences community will be attending this business conference\, attracting decision makers from biotech\, pharma and medtech\, agricultural and chemical industry as well as investors\, universities\, topnotch research institutes\, policymakers and competence providers. \n\n\n\nThe conference will feature an exciting programme providing vital insight into the global life sciences’ landscape\, one-to-one partnering\, a trade fair and more. \n\n\n\nEarly fee discounts are available until March 13. \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/knowledge-for-growth/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/03/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220428T090000
DTEND;TZID=Europe/Brussels:20220428T180000
DTSTAMP:20260526T205746
CREATED:20220210T105733Z
LAST-MODIFIED:20220210T105735Z
UID:3929-1651136400-1651168800@www.europabio.org
SUMMARY:AseBio Investor Day 2022 | Madrid
DESCRIPTION:Spanish biotechnology makes up 2.8% of global production and is cited 30% more than the global average in this area. Spain is ranked 9th in scientific production in biotechnology and has the highest percentage of scientific papers in high-impact journals of any country: 83.3%. \n\n\n\nIn 2018\, the biotechnology sector invested nearly €770 million in R&D\, 71% from biotech companies. Biotech companies were ranked first in Spain in 2018 for R&D investment in industrial sectors\, surpassing the pharmaceutical sector for the first time. The year-on-year increase in R&D investment in 2018 was 13%\, among the five fastest-growing sectors in R&D investment in Spain. \n\n\n\nAseBio Investor Day is the leading event allowing Spanish innovative biotechnology projects to be introduced to an audience of leading international investors and pharmaceutical & industrial companies. \n\n\n\nThe event is organized by AseBio\, the Spanish Bioindustry Association. EuropaBio members are entitled to a discount (please liaise with Martina Cilia for more information: m.cilia@europabio.org).
URL:https://www.europabio.org/event/asebio-investor-day-2022-madrid/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/02/Zoom-Banner-NAC-2022-600-×-200px-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220422T140000
DTEND;TZID=Europe/Brussels:20220422T160000
DTSTAMP:20260526T205746
CREATED:20220420T130047Z
LAST-MODIFIED:20220420T132311Z
UID:4343-1650636000-1650643200@www.europabio.org
SUMMARY:ESAB Webinar:  Advances in the Analysis of Enzymatic Reactions and Finding New Enzymes
DESCRIPTION:Programme / Speakers        \n\n\n\n14:00 – 14:30: Droplet Microfluidics with Mass Spectrometry for High-Throughput Enzyme Reaction Analysis \n\n\n\nProf. Dr. Robert T. KennedyDepartment of Chemistry\, University of Michigan\, Ann Abor\, MI 48109\, USA \n\n\n\n14:30 – 15:00: Biomolecular engineeDroplets-on-demand platforms for the high-throughput characterisation of functional enzymes \n\n\n\nDr. Fabrice GielenDepartment of Physics\, Living Systems Institute\, University of Exeter\, UK \n\n\n\n15:00 – 15:30: Measuring Enzyme Kinetics\, Inhibition\, and Allostery using Isothermal Titration Calorimetry \n\n\n\nProf. Dr. Anthony K. MittermaierDepartment of Chemistry\, McGill University\, Montreal\, QC\, Canada  \n\n\n\n15:30 – 16:00: Redesign of oxidative enzymes for the biocatalytic valorisIdentification of diverse enzymes by screening biodiversity using innovative in silico approaches: example with the Amine Dehydrogenase family (MODAMDH Project)  \n\n\n\nDr. Carine Vergne-VaxelaireGénomique Métabolique UMR8030\, Genoscope\, CEA\, Univ Evry\, Université Paris-Saclay\, France \n\n\n\nFlyer \n\n\n\nAbstracts and Short Bios of the speakers \n\n\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/esab-webinar-advances-in-the-analysis-of-enzymatic-reactions-and-finding-new-enzymes/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/04/fd-e1650460929130.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220406T140000
DTEND;TZID=Europe/Brussels:20220406T151500
DTSTAMP:20260526T205746
CREATED:20220315T155237Z
LAST-MODIFIED:20220323T095447Z
UID:4186-1649253600-1649258100@www.europabio.org
SUMMARY:Rare Conversations: Game changing opportunities for the R&D community to address existing challenges in rare diseases
DESCRIPTION:Join the inaugural episode of the new Rare Conversations event series in 2022\, aimed at powering the next decade of rare disease innovation in Europe. \n\n\n\nThe first episode will be focused on game-changing opportunities for the R&D community to address existing challenges in rare diseases. The aim is to understand what is the basis needed to build the foundations for the future innovative rare disease ecosystem. \n\n\n\nThe event\, organized by Alexion\, AstraZeneca Rare Disease\, in cooperation with the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)\, will revolve around discussions on how the revision of the OMP Regulation can create a space for opportunities for scientific progress. \n\n\n\nBlock your calendar for 6th April from 14.00 – 15.15 CET. More information and the registration link will be shared with you shortly. \n\n\n\nAbout “Rare Conversations”Rare Conversations is an event series organized by Alexion to educate on rare diseases and facilitate multi-stakeholder exchange\, tackling timely topics of interest such as the revision of the OMP Regulation. Rare Conversations aims to unite and engage the rare disease community\, including key stakeholders in Brussels and EU Member States. Since its inception in December 2020\, four Rare Conversations have taken place\, each in cooperation with a different partner and focused on specific topics\, such as COVID and rare diseases\, the specificities of research in rare disease\, and EU and national value assessment for orphan drugs. People with rare diseases always stay at the centre of our activities and are part of every event.
URL:https://www.europabio.org/event/rare-conversations-2022/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/03/Event-Banners-3-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220327T080000
DTEND;TZID=Europe/Brussels:20220329T170000
DTSTAMP:20260526T205746
CREATED:20220317T125220Z
LAST-MODIFIED:20220317T125252Z
UID:4208-1648368000-1648573200@www.europabio.org
SUMMARY:Crop Innovation & Business conference
DESCRIPTION:On March 27-29\, 2022 the CROP Innovation & Business (CropIB) conference will take place in Ghent\, Belgium. CropIB is a C-level  conference for management\, entrepreneurs\, leading scientists\, investors and legal experts from the international Ag-Bio industry.  \n\n\n\nDuring the 3-days conference the most influential trends that will affect agricultural research\, crop innovation and value chain strategies will be addressed including precision and indoor farming\, artificial intelligence\, consolidation\, economic growth and sustainability. \n\n\n\nThe goal of the conference is to inspire\, to initiate collaboration and innovation and to promote an open exchange of information. Elements like innovator pitches from startups\, the involvement of young scientists and entrepreneurs will be part of the program. \n\n\n\nWhom to meet:Around 200 delegates (CEOs\, CSOs\, Business executives\, heads of R&D/Biotech\, legal firms\, key scientists\, policy makers and investors) from the international Ag-Bio industry will be present from around 20 countries representing over a 100 different organisations. \n\n\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/crop-innovation-business-conference/
LOCATION:Old Fish Market (Oude Vismijn)\, Sint Veerleplein 5\, Ghent\, 9000\, Belgium
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/03/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220324T100000
DTEND;TZID=Europe/Brussels:20220324T120000
DTSTAMP:20260526T205746
CREATED:20220317T102344Z
LAST-MODIFIED:20230118T092658Z
UID:4196-1648116000-1648123200@www.europabio.org
SUMMARY:Safe and Sustainable-by-Design: a key tool to boost innovation and growth
DESCRIPTION:Hosted by MEP Maria Spyraki\n\n\n\nCo-chair of the European Parliament Intergroup on ‘Climate Change\, Biodiversity and Sustainable Development’\n\n\n\nIn October 2020\, The Chemical Strategy for Sustainability (CSS) was launched by the European Commission as a core element of the European Green Deal. As the CSS sets out a vision for the EU’s chemical policy\, to strive for a “toxic-free environment”\, it thus calls for a transition to chemicals that are Safe and Sustainable-by-Design (SSbD). The European Commission’s vision on Safe and Sustainable-by-Design moves towards a future where “Chemicals are produced/used in a way that maximizes their benefits to society while avoiding harm to planet & people and production and use of safe and sustainable chemicals in Europe becomes a benchmark worldwide”\, as put forward in the Chemicals Strategy for Sustainability. \n\n\n\nTherefore\, the SSbD concept can be turned into a mobilizing power driving for innovation and accelerating the transition towards the Sustainable Development Goals (SDGs)\, circularity and climate neutrality. For this reason\, it is crucial that the criteria for chemicals that are Safe and Sustainable-by-Design address the three pillars of sustainability – environmental\, social and economic factors – and take a life cycle approach. Moreover\, a holistic and multistakeholder approach of different sectors and key players needs to be taken into consideration to achieve an inclusive and successful transition towards chemical that are Safe and Sustainable-by-Design. \n\n\n\nIn this regard\, the European Parliament Intergroup on “Climate Change\, Biodiversity and Sustainable Development”\, in collaboration with Cefic\, is co-organizing an online event aiming at encouraging strong involvement\, dialogue and close cooperation among different stakeholders on the SSbD issue. The event will provide the opportunity to explore concrete examples on chemical innovation in the industry sector\, while also creating an open discussion between EU Institutions\, the NGO community and other stakeholders. \n\n\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/safe-and-sustainable-by-design-a-key-tool-to-boost-innovation-and-growth/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/03/Event-Banners-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220323T140000
DTEND;TZID=Europe/Brussels:20220323T150000
DTSTAMP:20260526T205746
CREATED:20220308T174146Z
LAST-MODIFIED:20220308T174147Z
UID:4172-1648044000-1648047600@www.europabio.org
SUMMARY:Rare Paediatric Neurological Diseases: A Focus on Europe
DESCRIPTION:Rare paediatric neurological conditions are debilitating diseases with significant impact on the daily lives of children and their families. Most rare diseases have neurological symptoms\, and about 90% of those affecting children have major neurological effects limiting the ability to achieve key cognitive and physical development milestones. \n\n\n\nTo highlight policy priorities for improving care\, patient outcomes and quality of life\, Economist Impact\, sponsored by PTC Therapeutics undertook a project to better understand how these disorders affect the lives of patients and their families. The resulting report ‘Rare paediatric neurological diseases: A focus on Europe’ highlights the difficulties in achieving a timely and accurate diagnosis\, as well as the numerous challenges to providing adequate care and support. It concludes that policymakers should work\, together with other stakeholders\, to develop a rare diseases healthcare ecosystem that is sufficiently resourced and organized to enable even the most complex conditions to be assessed and managed expeditiously.
URL:https://www.europabio.org/event/rare-paediatric-neurological-diseases-a-focus-on-europe/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/03/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220303T100000
DTEND;TZID=Europe/Brussels:20220303T133000
DTSTAMP:20260526T205746
CREATED:20220125T111412Z
LAST-MODIFIED:20220301T114053Z
UID:3732-1646301600-1646314200@www.europabio.org
SUMMARY:National Associations Council Summit 2022 | Biotechnology: Delivering Europe's Industrial Strategy Across Sectors
DESCRIPTION:EuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. \n\n\n\nThe NAC represents biotechnology priorities across Europe’s Member and partner countries\, working together to build long term economic and societal benefit from biotechnology across sectors. \n\n\n\nThe 2022 EuropaBio National Associations Council (NAC) Summit (France) focuses on how biotech is delivering the industrial strategy through national development. \n\n\n\nNational Associations\, biotech companies\, policy makers and others will discuss the commercial pathways for healthcare biotechnology to deliver innovative therapeutics to patients\, and for industrial biotechnology to drive economic growth and market development. \n\n\n\nNAC Summit outcomes will be key policy and initiative recommendations at national and EU level for the successful societal and economic performance of biotechnology across sectors. \n\n\n\nWho should take part? If you support development of the biotech community at national or European level\, or are a biotech company of any size\, get involved and help debate the key drivers for successful economic delivery. \n\n\nAgenda \n10:00 – Opening session: French presidency priorities for biotechnology \nWelcome: Tineke Van hooland\, Chair EuropaBio National Associations Council\n· Healthcare presidency priorities\n· Industrial biotech and bioeconomy priorities\n \n10:20 – Healthcare biotechnology: Innovative therapeutics to patients in Europe \n   Organisations: European Parliament\, Sanofi\, Tree Frog Therapeutics\, HBio\, AseBio\, Bio.be\, EuropaBio\, PTC Therapeutics  \n Topic 1: Building from Europe’s innovation; transforming research to a sustainable and accessible healthcare  \n   Chair: Ana Sofia Antunes\, mabdesign\n   Company statements: Sanofi\, Tree Frog Therapeutics\n   How do national and EU initiatis and policies help move research advances through to patient uptake? What needs to happen in order to bring momentum and investment into technologies\, skills and infrastructure for next generation therapies in Europe?\n \nTopic 2: Innovation and healthcare across borders; Delivering Europe’s strength to all\n   Chair: Chloé Evans\, France Biotech\n   Company statement: Sanofi\, PTC Therapeutics\n   How does Europe enable cross-border healthcare? The panes discusses the policy\, regulatory frameworks and national collaborations that can bring ultimate benefit for European citizens.\n \n11:30 – Break \n11:45 – Industrial biotechnology and bioeconomy: Growth and innovation to market \n   Organisations: Circular Bio-based Europe Joint Undertaking\, AFYREN\, ITERG & PIVERT & IMPROVE\,  France 2030\, BASF\, HollandBio\, Remilk\, Bio-Base Europe Pilot Plant \nTopic 3: Acceleration of business and manufacturing; investment and policy\n   Chair: Christophe Luguel\, IAR\n   Company statements: AFYREN\, BASF\n   How does Europe ride the wave of manufacturing from biological platforms? The panel discusses national initiatives and EU policies and programmes that enable long term investment into large scale manufacture and ensuring a competitive next generation industrial landscape.\n \nTopic 4: Novel foods; A pathway to market in Europe\n   Chair: Agnes Borg\, EuropaBio\n   Company statements: BASF\, Remilk\n   Novel foods are a core part of Europe’s future sustainability and competitiveness\, offering an opportunity to capitalise on world leading research. The panel will discuss the critical policy and regulatory framework that will enable investment in early stage innovators and for large scale production for European and global market performance.\n \n13:00 – Closing plenary: Looking ahead for European industrial delivery from biotechnology\n   Chair: Claire Skentelbery\, EuropaBio\n   Chairs and companies from across the sessions discuss key messages from the meeting and make recommendations for policies and initiatives at national and European levels to deliver economic contribution from biotechnology.\n \n13:30 – Close  \n\n\n\n\n\n\n\n\n\nSpeakers \n Tomislav Sokol\, Member of the European Parliament\, EPP\, Croatia\nTomislav Sokol was born in Zagreb in 1982. He obtained his first degree in law at the Faculty of Law\, University of Zagreb\, in 2006\, magna cum laude. He then obtained a Masters of Law (LL.M.) specialising in European Union Law at the Katholieke Universiteit Leuven (KUL)\, Belgium\, in 2009\, magna cum laude. He defended his PhD at KUL\, dealing with free movement of cross-border health care services in the EU and its impact on national health insurance systems in 2014.\nHe was an Assistant Minister in the Ministry of Science and Education in 2017\, after which he became a Member of the Croatian Parliament. He was a Member of the Croatian Parliament until July 2019\, when he became a Member of the European Parliament. He is a Member of the Committee on the Internal Market and Consumer Protection (IMCO) and a Substitute Member of the Committee on Regional Development (REGI).\nSo far\, he has published around 20 papers and 1 book on issues concerning EU law\, including several articles in European journals\, such as the European Law Review and the European Law Journal. He has presented papers at many international conferences and worked on different research projects. Previously\, he worked in a legal practice and is currently a Senior Lecturer at the Zagreb School of Economics and Management where he has taught Introduction to European Union and Principles of Law courses since the academic year 2010/2011. He is also an assistant professor at the Catholic University of Croatia where he has taught since the academic year 2016/2017. His areas of professional interest include the law of the European common market\, EU health law\, competition law\, International and European social law and International and European trade law.  \n Ana Sofia Antunes\, Head of International Relations & Scientific Events\, MabDesign\nAna Antunes obtained her PhD in Microbiology from the Lisbon University. She has an international career having worked both in research institutions like Institut Pasteur à Paris\, or Instituto de Tecnologia Quimica e Biologica (ITQB\, Portugal) as well as pharmaceutical companies as Novartis Vaccines & Diagnostics (Siena\, Italy). Through her career\, she has been involved in the organization of scientific events such as workshops and dedicated conferences. Ana is Head of International Relations & Scientific Events at MabDesign. \n Elke Duwenig\, Senior Biotechnology Expert Regulatory / Public & Government Affairs\, Nutrition & Health\, BASF \nDr. Elke Duwenig is an inspiring senior expert\, skilled in biotechnology and innovation on agricultural and life science challenges\, with passion for sustainable solutions. She is currently active in Regulatory and Government Affairs for Industrial Biotechnology at Nutrition & Health\, BASF SE. She was also an expert lead in the Corporate Renewable Raw Material Roadmap at BASF. Elke gives expert guidance for strategies and roadmaps as well as for R&D projects and sales products. She is strongly engaged in legislation and authority work to safeguard biotech products and opening markets together with EuropaBio\, EU SFI\, FEFANA\, AMFEP\, and other trade associations and think tanks like BIC\, ILSI and AFSI\, both in the EU and globally.\nElke studied biology and chemistry at the University of Münster\, Germany and Stanford University\, USA. She graduated and completed her doctorate in molecular plant physiology at the Institute for Gene-Biological Research (Institut für genbiologische Forschung) IGF\, Berlin\, and did two postdocs at the Max-Planck Institute in Golm and the University of Freiburg\, Germany\, before joining BASF. \n Denis Chéreau\, Chief Executive Officer\, ITERG & PIVERT & IMPROVE \nDenis Chéreau holds a Ph.D. in microbiology (production of single-cell protein by solid state fermentation).\nAfter 15 years in the production and marketing of enzymes\, he moved for 14 years in the starch industry as technical and plant manager in France and the USA.\nHe is currently general manager of 3 R&D centres : IMPROVE expert in plant based protein\, PIVERT expert in green chemistry and biotechnologies and ITERG French institute of oil seeds and plant based fat processing. \n Nicolas Sordet\, Co-founder & Chief Executive Officer\, AFYREN \n Nicolas Sordet is co-founder and Chief Executive Officer of AFYREN since 2014. He holds a Master’s degree in Corporate Finance and Financial Markets from the Grenoble Management School.\nHe put his financial knowledge into practice by holding several positions in Investment banks and Financial Institutions in Switzerland\, in the US and in Asia.\nHe was Deputy Chief Executive Officer of Link Securities from 2006 to 2013\, then Private Equity/Venture Capital and Financing Advisor from 2013 to 2014. He has been able to apply his financial expertise and experience for AFYREN development. \n Virginia Puzzolo\, Head of Programme\, Circular Bio-based Europe Joint Undertaking \n Virginia holds a doctoral degree in plant ecology and biology. For the last 20 years\, she has been developing and implementing the EU research and innovation policies in several EU institutions. Virginia’s previous professional experience includes the European Commission’s Research Executive Agency\, the Enterprise Directorate-General of the European Commission\, the EU’s Joint Research Centre\, and the Italian Research Forest Management Institute.  \n Ion Arocena Vélez\, Director General\, AseBio \nIon Arocena joined AseBio\, the Spanish Bioindustry Association\, in 2016 as general manager. He is a biotechnologist by training and completed his studies with an executive MBA at EOI Business School\, Madrid.\nHe started off at the Technology Transfer Office of the Universidad Autónoma de Madrid\, offering Technology Watch services to SMEs. His next position was at Genoma España\, a Government Owned Agency promoting the protection of Intellectual Property and the transfer of such results to companies.\nFrom 2006 to 2015\, he was part of the funding team of Suanfarma Biotech SGECR\, a venture capital firm\, specialized in life science\, where he was responsible for the evaluation of investment opportunities. \n Mathieu Brandibat\, National coordinator of the “Recyclability” and “Biosourced” acceleration strategies\, France 2030\nMathieu Brandibat is an agronomist. Specialized in the management of information systems\, he worked within fields such as the valorization of innovation and the utilities. Following a duty at the ADEME (French Agency dedicated to the ecological transition)\, he is now part of the Prime Minister services (General Secretariat for Investment – SGPI) involved in the national plan “France 2030” dedicated to pave an  ambitious way for R&D\, innovation and industrialization\, as the national coordinator for strategies « recycling and reincorporation of materials » and « Biobased products and industrial biotechnologies – sustainable fuels”. \n Wieteke Wouters\, Programme Director\, HollandBIO\nWieteke Wouters is program director of HollandBIO\, the Dutch biotech industry association. HollandBIO’s mission is that biotech is able to contribute maximally to a sustainable and healthy society.  With the motto “challenge the status quo”\, HollandBIO takes on the obstacles that stand in the way of the sector’s innovative frontrunners.\nPrior to joining HollandBIO\, Wieteke worked at a consultancy firm specialized in health and sustainability. Wieteke began her career at a Leiden based biotech start-up. Wieteke graduated in Biomedical Sciences at Utrecht University and specialized in Science and Business Management. \n Kevin Alessandri\, PhD\, Co-founder and CTO\, TreeFrog Therapeutics \nInitially trained in biophysics at the Ecole Normale Supérieure\, Kévin Alessandri completed in 2013 a PhD thesis on cell encapsulation technologies at the Institut Curie\, France. He then continued his rexearch at the University of Geneva\, Switzerland\, where he met Maxime Feyeux\, an expert in pluripotent stem cell biology. Together\, they invented a biomimetic cell culture technology – C-Stem –  allowing for the mass-production of cell therapies.  Alessandri and Feyeux co-founded TreeFrog Therapeutics in 2018\, with the aim of providing access to safer\, more efficient and more affordable cell therapies to millions of patients. Following a recent $75M Series B financing\, Kevin Alessandri will move to Boston\, USA\, in September 2022 to lead the newly created U.S. subsidiary of TreeFrog Therapeutics.  \n Chloe Evans\, Market Research Manager & International Relations\, France Biotech \nChloé Evans is currently Head of Market Research and International Relations at France Biotech. Since 2016\, she has been coordinating market research and industry publications for the association\, conducting policy impact assessments and business intelligence. She also helps support and coordinate some of France Biotech’s working groups and the Association’s actions on new policies and advocacy for healthcare and biotechnology industries. Since 2019\, she oversees international relations with both European and global associations and stakeholders. Prior to joining France Biotech\, Chloé worked in strategy consulting for the healthcare sector at Bionest Partners and then with D&Consultants where she worked on various strategy and marketing projects for technology transfer offices\, pharma and biotech companies.\nMs. Evans holds a degree in Biochemistry (BSc) from the University of Manchester (UK) and a Master’s degree in European Business and Management from ESCP Europe Business school (London/Paris).  \n Frédéric Druck\, Managing Director\, essenscia wallonia /brussels – Secretary General\,  bio.be/essenscia  \nSince September 2016\, Frédéric Druck (55) is the Secretary General of bio.be/essenscia\, the association of companies active in Belgian life sciences and biotechnologies industry. Frédéric is also Managing Director of essenscia wallonia and of essenscia brussels\, the regional associations of the Belgian federation for chemistry and life sciences industry “essenscia”. Finally\, he is chairing the Board of aptaskil\, the training center for chemistry and life sciences in Wallonia  as well as the Board of the EU Biotech Campus\, a multi training operators platform that is part of the Belgian Recovery Plan.\nFrédéric joined essenscia after spending almost 10 years at BioWin\, the health cluster of Wallonia (Belgium) where he mainly developed international partnerships with biotech clusters from the US\, China and Europe. During this period\, he used to Chair the Council of European Bio Regions (CEBR) and the European Diagnostic Clusters Alliances (EDCA).\nFrédéric did his whole career in Public Relations and Public Affairs positions in the biopharma industry as well as in sector-related associations. \n Liam Sharon\, Head of food technology\, Remilk \nMSc food molecular biology from the Hebrew university Jerusalem\, Israel. BSc Food science\, technology and Management from Heriot Watt University Edinburgh\, Scotland. More than 15 years’ experience in the food industry with emphasis on dairy and product development. Joined Remilk as a Head of food R&D one year ago \n Hendrik Waegeman\, Head of Business Operations\, Bio Base Europe Pilot Plant\nHendrik Waegeman obtained a master degree in biochemical engineering at Ghent University (2007) and holds a PhD in Applied Biological Sciences-Chemical Engineering (2011)\, also obtained at Ghent University. During his doctoral research he metabolically engineered Esherichia coli to improve recombinant protein production. During his post-doctoral research\, Hendrik Waegeman was involved in a number of projects that focused on the fermentative production of specialty carbohydrates. He is also a co-founder of the company Inbiose NV\, founded in 2013\, which develops fermentatively produced specialty carbohydrates such as human milk oligoscaccharides.  In 2012 he was guest lecturer at the University of Incheon\, South-Korea where he lectured a course on Metabolic Engineering and Modelling of Micro-organisms. Since 2012\, he has a position at Bio Base Europe Pilot Plant\, a multi-purpose pilot facility in the Port of Ghent in Belgium where he has worked as Head of Business Development and is now Head of Business Operations.\nHendrik is also board director of Inbisoe NV\, Bio.be (the cluster of Belgian biotech companies) and Biobased Industries Consortium (BIC\, the private partner in the joint undertaking Horizon2020-BBI and the upcoming joint undertaking CBE (Circular Bio-based Europe). \n Stamatiki Kritas\, Research & Development\, Innovation Management\, HBio Cluster  \n Christophe Luguel\, Head of International Affairs\, Cluster Industries & Agro-ressources (IAR) \n Agnes Borg\, Industrial Biotechnology Director\, EuropaBio \n \n\n\n\n\n\n\n\n\n\n\nShould you encounter any issues with the reception of the confirmation email\, please contact Martina CILIA (m.cilia@europabio.org).\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/nac-summit-2022/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/02/Zoom-Banner-NAC-2022-600-×-200px-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220225T100000
DTEND;TZID=Europe/Brussels:20220225T120000
DTSTAMP:20260526T205746
CREATED:20220221T112817Z
LAST-MODIFIED:20220221T113151Z
UID:4039-1645783200-1645790400@www.europabio.org
SUMMARY:ESAB Webinar: Enzyme Engineering
DESCRIPTION:Preliminary Programme / Speakers        \n\n\n\n10:00: Enzyme evolution for efficient biosynthesis of biofuel and medicine \n\n\n\nProf. Dr. Yan FengDistinguished Professor and Vice Dean\, School of Life Science and Biotechnology\, Department of Biochemistry and Molecular Biology\, Shanghai Jiao Tong University\, Shanghai\, China \n\n\n\n10:30: Biomolecular engineering with microbial transglutaminase \n\n\n\nProf. Dr. Noriho KamiyaDirector\, Division of Biotechnology\, Center for Future Chemistry (CFC)\, Department of Applied Chemistry\, Faculty of Engineering\, Kyushu University\, Japan \n\n\n\n11:00: Surfing the wave of oxyfunctionalization chemistry by engineering fungal unspecific peroxygenases \n\n\n\nProf. Dr. Miguel AlcaldeDepartment of Biocatalysis\, Institute of Catalysis\, Consejo Superior de Investigaciones Científicas (CSIC)\, Madrid\, Spain \n\n\n\n11:30: Redesign of oxidative enzymes for the biocatalytic valorisation of biomass \n\n\n\nProf. Dr. Marco W. FraaijeProgramme Director MSc Biomolecular Sciences\, Molecular Enzymology Group\, University of Groningen\, Groningen\, The Netherlands \n\n\n\nFlyer \n\n\n\nAbstracts and Short Bios of the speakers \n\n\n\n\n\n\n\n\nREGISTER HERE
URL:https://www.europabio.org/event/esab-webinar-enzyme-engineering/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/02/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220126T103000
DTEND;TZID=Europe/Brussels:20220126T130000
DTSTAMP:20260526T205746
CREATED:20211216T100649Z
LAST-MODIFIED:20220113T150518Z
UID:3584-1643193000-1643202000@www.europabio.org
SUMMARY:Introducing the Innovative Health Initiative: Europe’s new partnership for health
DESCRIPTION:The Innovative Health Initiative (IHI) aims to build on the successes of the Innovative Medicines Initiative (IMI) and will hold a launch event in a virtual setting on Wednesday\, January 26th\, from 10:30am to 1:00pm. \n\n\n\nThe event will be broken up into two sessions: \n\n\n\nIn the first session\, IHI Executive Director Dr Pierre Meulien will present IHI and explain why we are launching a new European partnership for health. He will also describe what’s new compared to the Innovative Medicines Initiative (IMI)\, and what will stay the same. IHI staff will then present opportunities for stakeholders to get involved in IHI\, for example by applying to become a member of the IHI Science and Innovation Panel (SIP)\, or by becoming an expert evaluator. They will also offer a preview of the draft topics under consideration for inclusion in the first IHI call for proposals. \n\n\n\nThe second session will feature a high-level discussion during which representatives of the IHI partners\, namely the European Commission\, COCIR\, EFPIA\, Vaccines Europe\, EuropaBio and MedTech Europe\, will present their vision for IHI. \n\n\n\nBoth sessions will include time for questions from participants. \n\n\n\n \n\n\n\n\nMore info here
URL:https://www.europabio.org/event/introducing-the-innovative-health-initiative-europes-new-partnership-for-health/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/12/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220111T103000
DTEND;TZID=Europe/Brussels:20220111T114500
DTSTAMP:20260526T205746
CREATED:20211220T114942Z
LAST-MODIFIED:20211220T115154Z
UID:3592-1641897000-1641901500@www.europabio.org
SUMMARY:How can stronger IP in EU Free Trade Agreements boost productivity and economic growth in Europe?
DESCRIPTION:You are invited to join a virtual event seeking to discuss the economic and societal value of intellectual property rights (IPRs) for Europe. \n\n\n\nHow do IPRs in EU Free Trade Agreements (FTAs) support EU strategic resilience and global competitiveness in a post-COVID world? What are the concrete benefits of robust IPRs for EU member states? How important is IP for innovation\, in particular for the green and digital societal transformations? Why should IPRs be given a more prominent role in EU policy making\, especially when it comes to EU FTAs? These are some of the questions that our guest speakers will address during the panel discussion. \n\n\n\nFollowing the presentation of a recent ECIPE report\, the speakers will explore how stronger IPR provisions in EU FTAs contribute to EU and EU Member State economic and societal ambitions. \n\n\n\nSpeakers: \n\n\n\nFredrik Erixon\, Director\, ECIPEMaria Martin-Prat\, Deputy Director – General\, DG TRADENathalie Moll\, Director General\, EFPIALuisa Santos\, Deputy Director General\, BusinessEurope\n\n\n\nIf you have any questions or require additional information\, please contact ECIPE at events@ecipe.org \n\n\n\nWe look forward to virtually meeting you on 11 January! \n\n\n\n\nRegister
URL:https://www.europabio.org/event/how-can-stronger-ip-in-eu-free-trade-agreements-boost-productivity-and-economic-growth-in-europe/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211213T140000
DTEND;TZID=Europe/Brussels:20211213T150000
DTSTAMP:20260526T205746
CREATED:20211116T143909Z
LAST-MODIFIED:20211216T093602Z
UID:3429-1639404000-1639407600@www.europabio.org
SUMMARY:EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration
DESCRIPTION:The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s\, and research from the 1990s started to reveal its potential as a therapeutic tool. \n\n\n\nmRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years\, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development\, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications. \n\n\n\nWe bring together protagonists from across the spectrum\, including:• Ingmar Hoerr\, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart\, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel\, Senior Manager\, Manufacturing & Technology\, Catalent Biologic
URL:https://www.europabio.org/event/europabio-25th-anniversary-mrna-a-voyage-of-discovery-and-celebration/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211202T090000
DTEND;TZID=Europe/Brussels:20211202T170000
DTSTAMP:20260526T205746
CREATED:20210910T104509Z
LAST-MODIFIED:20211215T092436Z
UID:3084-1638435600-1638464400@www.europabio.org
SUMMARY:8th Biorizon Annual Event on Bio-Aromatics
DESCRIPTION:December 2nd\, major industrial players\, small to medium sized enterprises\, government officials and research and technology organisations from all over the world will join Biorizon Shared Research Center to discuss the latest progress in the field of bio-aromatics and to elaborate on opportunities to accelerate biobased business together. Biorizon invites you to join\, either on-site in Rotterdam\, or remotely.  \n\n\n\nOver the past years\, this event has evolved into a must-attend event for anyone who’s interested in renewable aromatics. Last edition attracted 308 participants from 29 countries that engaged in 163 matchmaking sessions. \n\n\n\nWhat to expect from this year’s hybrid annual event on 2 December: \n\n\n\nShort\, interactive plenary presentations that feature the progress that Biorizon has made in the scaling up of the production of bio-aromatics with premium properties. Plus a keynote speech of a major brand owner you don’t want to miss (t.b.c.).By popular demand\, we have maximized the opportunity to arrange matchmaking sessions that can be scheduled as from now. Meet representatives of the entire bio-aromatic value chain from all over the world!
URL:https://www.europabio.org/event/8th-biorizon-annual-event-on-bio-aromatics/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/09/Event-Banners-26.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211130T140000
DTEND;TZID=Europe/Brussels:20211130T151500
DTSTAMP:20260526T205746
CREATED:20211103T141708Z
LAST-MODIFIED:20211119T105146Z
UID:3401-1638280800-1638285300@www.europabio.org
SUMMARY:EFIB 2021 | Vienna Statement Launch
DESCRIPTION:The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members\, with policy asks and actions critical in the short term for Europe’s delivery of a bioeconomy. \n\n\n\nDeveloped through 2021 and published at EFIB in Vienna\, the statement includes:• Next generation Europe: An urgent call to action• Industrial biotechnology: Proving its value to society\, environment and economy• The clock is ticking for European climate and competitive ambitions• Time is now – EFIB Vienna Statement requests for modernisation of regulation and policy\, Education and awareness and financing innovation \n\n\n\nModerator: \n\n\n\n• Dr Claire Skentelbery\, Director General\, EuropaBio \n\n\n\nSpeakers: \n\n\n\n• Stefan Buchholz\, Senior Vice President R&D Nutrition & Care\, Evonik \n\n\n\n• Elke Duwenig\,  Senior Biotechnology Expert Regulatory / Public & Government Affairs\, Nutrition & Health\, BASF \n\n\n\n• Jim Philp\, Science and Technology Analyst\, OECD \n\n\n\n• Video message by Simone Schmiedtbauer\, Member of the European Parliament\, Group of the European People’s Party\, Austria \n• Video message by Virginijus Sinkevičius\, European Commissioner for Environment\, Oceans and Fisheries \n\n\n\nWe invite you now to join us for the wider launch of the EFIB Vienna Statement – to set the challenge for Europe and discuss what this means for policy\, regulation\, investment and innovation. \n\n\n\nJoin us on 30 November at 14:00 CET and be part of the conversation in the 12 months until the next EFIB conference in Vilnius\, Lithuania\, October 2022. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/efib-2021-vienna-statement-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211130T080000
DTEND;TZID=Europe/Brussels:20211201T170000
DTSTAMP:20260526T205746
CREATED:20210624T111915Z
LAST-MODIFIED:20220204T161044Z
UID:2778-1638259200-1638378000@www.europabio.org
SUMMARY:16th European Bioplastics Conference 2021
DESCRIPTION:The European Bioplastics Conference\, taking place from 30 November to 1 December 2021 in Berlin\, is the leading business and discussion forum in Europe for the global bioplastics sector. With more and more brands and manufacturers embracing the potential of biopolymers\, and with policy makers increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries\, this is the time to put bioplastics on top of the agenda of a bio-based circular economy in Europe and beyond. The 16th conference edition will focus on the latest innovations in bio-based and biodegradable plastics\, the current political landscape as well as on environmental aspects\, and opportunities for growth.
URL:https://www.europabio.org/event/16th-european-bioplastics-conference-2021/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/NL-Size-22.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20211118T090000
DTEND;TZID=Europe/Brussels:20211118T150000
DTSTAMP:20260526T205746
CREATED:20211110T145054Z
LAST-MODIFIED:20211118T130043Z
UID:3419-1637226000-1637247600@www.europabio.org
SUMMARY:HealthDay.si Conference 2021: Biotech Meets Digital
DESCRIPTION:Biotechnology and digital are getting closer. Due to the high development of both segments\, Slovenia has a great global opportunity in this convergent field of medicine. Can good experiences from the digital healthcare ecosystem be linked to biotechnologies? Can we create something in this space that could be globally relevant? Can a new “digital Krka” or a new “digital Lek” be created in this area? \n\n\n\nIn this year’s HealthDay.si conference we will focus on the digitization of biotechnological solutions related to medicine and health\, with emphasis on diagnostics\, advanced cell and gene therapies. \n\n\n\nSelected speakers\, including international experts and CEOs of established companies\, will share their expertise and touch upon additional topics starting with financing growth by a seed round\, PPPs in health/research and ranging to secondary use of health data\, prevention\, value-based health system\, ATMP therapies\, digitalization of genomic data and artificial intelligence.
URL:https://www.europabio.org/event/healthday-si-conference-2021-biotech-meets-digital/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/HealthDay-e1636555980832.png
END:VEVENT
END:VCALENDAR